Castle Biosciences DecisionDx-CMSeq

Castle Biosciences has launched its DecisionDx-CMSeq test, which uses next-generation sequencing to identify somatic mutations in BRAF and NRAS, two genes linked to cutaneous melanoma. The DecisionDx-CMSeq test will provide additional information to compliment the firm's DecisionDx-Melanoma gene expression profile (GEP) test that predicts individual risk of melanoma recurrence in patients. The test can be ordered with the DecisionDx-Melanoma GEP test or as a standalone request.